<div id="readability-page-1"><div> SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (&#34;Innovent&#34;) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces updated data from the Phase 1 PoC clinical study of its first-in-class PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&amp;D code: TAK-928) in the treatment of advanced immunotherapy(IO)-resistant non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. An overview of the abstract information is provided below, and the full abstract is available here. More detailed results will be presented during the conference. Updated data from this PoC study conducted in China, showed that after extended follow-up, IBI363 continued to demonstrate a manageable long-term safety profile in IO-resistant NSCLC. Notably, the long-term follow-up data showed strong overall survival (OS) in both squamous NSCLC and adenoNSCLC, supporting the durable benefits driven by IBI363's unique dual mechanism of immune checkpoint blockade plus cytokine agonism.Based on the data from this study, IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC, the clinical trial design of which will also be presented at this ASCO. Pending regulatory communications, initiation of a global Phase 3 clinical study of IBI363 for IO-resistant non-squamous NSCLC is also planned.Updated PoC Clinical Data of IBI363 in Immunotherapy-Resistant Advanced NSCLCThe abstract at this conference reported updated data on IBI363 monotherapy in subjects with advanced NSCLC (ClinicalTrials.gov, NCT05460767). As of the follow-up cutoff date of November 20, 2025, a total of 136 subjects with NSCLC had received IBI363 monotherapy (2 μg/kg QW~4mg/kg Q3W).IBI363 Showed Robust Survival Benefits with a Long Tail Effect in IO-Resistant Squamous NSCLC<ul><li>All 67 squamous NSCLC patients had no known EGFR mutations. Among them, 28 patients received IBI363 at 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 31 patients received IBI363 at 3 mg/kg Q3W. In the 3 mg/kg Q3W dose group, the median PFS reached 10.1 (95%CI 6.0, 14.0) months, and the median OS achieved 18.2 (95%CI 10.7, NE; maturity 48.4%) months, with a 24-month OS rate of 47.8% (95%CI 28.7, 64.7).</li><li>Previously, in the TROPION–Lung01 study that also enrolled NSCLC patients previously treated with immunotherapy, the docetaxel (standard of care) control group achieved a median overall survival (OS) of 9.4 months and a 24–month OS rate of 14.8% in patients with squamous NSCLC. The long–term follow–up data of IBI363 demonstrate a highly competitive survival advantage.</li></ul>IBI363 Showed Potential for Long-Term Survival Benefits with a Long Tail Effect in IO-Resistant Wild-type AdenoNSCLC, Especially in Patients with a Smoking History<ul><li>Among the 58 patients with EGFR wild-type adenoNSCLC, 30 patients received IBI363 at 0.6 mg/kg Q2W or 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 25 patients received IBI363 at 3 mg/kg Q3W. In the 3 mg/kg dose group, the median PFS reached 4.2 (95%CI 3.0, 7.0) months, and the median OS achieved 15.2 months (95%CI 9.6, NE; maturity 56.0%), with a 24-month OS rate of 42.7% (95%CI 23.1, 61.0).</li><li>Smoking history may be an important influencing factor for the efficacy in immuno-resistant adenoNSCLC. In adenoNSCLC subjects with a smoking history, better survival benefits were observed. The median OS for smokers across all dose groups (n=31) reached 23.4 (95%CI 11.3, NE, maturity 48.4%) months.</li><li>Previously, in the TROPION–Lung01 study that also enrolled NSCLC patients previously treated with immunotherapy, the docetaxel (standard of care) control group achieved a median overall survival (OS) of 12.3 months and a 24–month OS rate of 21.7% in patients with non-squamous NSCLC. The long–term follow–up data of IBI363 demonstrate a highly competitive survival advantage.</li></ul>IBI363 Showed a Favorable Safety Profile in Long-Term Follow-up<ul><li>In the long-term follow-up of the overall population (n = 136), IBI363 demonstrated a favorable safety profile: treatment-emergent adverse events (TEAEs) of grade 3 or above were present in 48.5% of patients. The most common adverse events were mainly arthralgia (52.2%, ≥grade 3 3.7%), anemia (46.3%, ≥grade 3 4.4%), and rash (39.0%, ≥grade 3 8.8%), which were mostly controllable and manageable with mild-to-moderate AEs. No new safety signals were observed.</li></ul>Dr. Hui Zhou, Chief R&amp;D Officer (Oncology Pipeline) of Innovent, stated: &#34;Lung cancer remains the most common malignant tumor worldwide. Although immunotherapy has transformed the treatment landscape of NSCLC, therapeutic options are still very limited for patients without driver gene mutations who have failed immunotherapy, with overall survival typically less than 12 months. With longer follow-up, we are encouraged to see outstanding survival outcomes with IBI363 in IO-resistant NSCLC across both squamous and adenoNSCLC. These results further underscore the novel mechanism of IBI363 and its 'tailing effect' driven by dual immune checkpoint blockade and cytokine agonism. We hope it will offer a new treatment option for this large patient population and ultimately deliver long-term survival benefits.&#34;About IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein)IBI363 is a first-in-class PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and selectively activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm blocks PD-1 and selectively delivers IL-2 to the tumor.IBI363 is being evaluated in a series of clinical trials globally, led by a pivotal Phase II study in China in previously untreated acral and mucosal melanoma and a global multi-regional Phase III trial in immunotherapy-resistant squamous NSCLC. In parallel, multiple Phase Ib/II trials are evaluating IBI363 in NSCLC and CRC including the first-line and later line settings, and in additional tumor types. IBI363 has received two Fast Track Designations (FTD) from the U.S. FDA and three Breakthrough Therapy Designations (BTD) from China NMPA so far.In October 2025, Innovent entered into a license and collaboration agreement with Takeda, under which Innovent and Takeda will co-develop IBI363 (Takeda R&amp;D code: TAK-928) globally and co-commercialize IBI363 in the U.S., and Takeda will exclusively commercialize IBI363 worldwide other than the U.S. and greater China.About InnoventInnovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 5 assets in Phase III or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.Guided by the motto, &#34;Start with Integrity, Succeed through Action,&#34; Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.Forward-looking statementThis news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words &#34;anticipate&#34;, &#34;believe&#34;, &#34;estimate&#34;, &#34;expect&#34;, &#34;intend&#34; and similar expressions, as they relate to Innovent Biologics (&#34;Innovent&#34;), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. <img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0yMSZzbj1DTjY1MjUy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="16" height="16" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0yMSZzbj1DTjY1MjUy"/> View original content:https://www.prnewswire.com/news-releases/2026-asco-abstract-highlights-innovent-biologics-ibi363-pd-1il-2-bias-bispecific-fusion-protein-demonstrates-robust-survival-benefits-in-long-term-follow-up-of-poc-study-in-advanced-immunotherapy-resistant-non-small-cell-lun-302779647.htmlSOURCE Innovent Biologics</div></div>

信達生物

華夏中證生物科技主題ETF

易方達中證生物科技主題ETF

信達生物在 2026 年美國臨牀腫瘤學會（ASCO）年會上展示了 IBI363 的最新數據，這是一種 PD-1/IL-2α偏向雙特異性融合蛋白。第一階段的概念驗證研究顯示，在晚期免疫治療耐藥的非小細胞肺癌（NSCLC）中，IBI363 帶來了顯著的生存獲益，並且安全性良好。IBI363 在鱗狀 NSCLC 中的中位總生存期為 18.2 個月，在腺癌 NSCLC 中的中位總生存期為 15.2 個月。針對免疫治療耐藥的鱗狀 NSCLC 的全球第三階段研究即將開始，待監管溝通後進行

2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

MorningStar

廣發中證香港創新藥(QDII-ETF)

華夏上證科創板生物醫藥ETF

華寶恆生港股通創新藥精選ETF

博時恆生港股通創新藥精選ETF

天弘國證生物醫藥ETF

富國恆生港股通創新藥及醫療保健ETF

華夏恆生生物科技ETF(QDII)

國泰中證滬港深創新藥產業ETF

鵬華上證科創板生物醫藥ETF

國泰上證科創板創新藥ETF

生物科技ETF基金

華夏醫藥ETF

易方達滬深300醫藥ETF

華安恆生生物科技ETF

創新藥

國泰中證生物醫藥ETF

博時恆生醫療保健(QDII-ETF)

紐交所高增長板生物技術指數 ETF - First Trust

香港醫藥

匯添富國證港股通創新藥ETF

招商中證生物科技主題ETF

南方恆生生物科技ETF(QDII)

易方達恆生港股通創新藥ETF

2026 年 ASCO 摘要亮點：信達生物的 IBI363（PD-1/IL-2α偏向雙特異性融合蛋白）在長期隨訪的概念驗證研究中，針對晚期免疫治療耐藥的非小細胞肺癌顯示出顯著的生存益處